Immunotherapy has been seen to be an alternative for treating cancer since most cancers are immunogenic. The primary cells involved in the examination of the immune cancer are the T cells. They have the ability to identify the numerical and disparity in the quality that are existing on the antigens of cells that have undergone transformation. There is the cancer or testis (CT) type of tumor antigens that are the highest targets for therapy due to the special features they have. One of these characteristics is the ability to be considered as the neoantigens and their capability to extract immune responses that are just for cancer (Gjerstorff, Andersen and Ditzel 15775).
The CT antigens when in multiples can support the growth of the cancer cell. This is the oncogenic function of these testis antigens. There is also a connection between the CT antigen appearance and the cancer development. The CT antigen, in oncogenic cancer also partakes in vaccination, genomic integrity and adoptive T-cell therapy (Gjerstorff, Andersen and Ditzel 15779).
There are about eleven million people in the world who are diagnosed with cancer annually. There is the need to find the novel treatment of cancer. However, immunotherapy has been seen to be an option. A therapeutic cancer vaccine is a form of immunotherapy that has been seen to stimulate the immune response to identify and destroy the cancer cells (Almeida, Sakabe and deOliveira 816)
The melanoma antigen (MAGE-1 )is the first cancer antigen that was duplicated from the cells of a patient who had melanoma. The CT antigens, however, remain significant as cancer antigens and which are being used to carry out vaccination. Particular focus is being given to these antigens such that there is a database for collecting and presenting the information found on the CT antigens. The database contains various information that can be required by any user on the CT antigens. There is the section on the gene and protein and the expression area as well (Almeida, Sakabe and deOliveira 818). The database is operated on a free software database server (Almeida, Sakabe and deOliveira 819)
Works Cited
Almeida, Luiz Gonzaga, et al. "CT database: a knowledge-base of high-throughput and curated data on cancer-testis antigens." Nucleic Acids Research (2008): 816-819.
Gjerstorff, Morten F, Mads H Andersen and Henrik J Ditzel. "Oncogenic cancer/testis antigens: prime candidates for immunotherapy." Impact Journals (2015): 15772-15781.
